Fulvestrant
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-FULVESTRANT |
|---|---|
| Type | Drug |
| Aliases | FaslodexФулвестрант |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | SERD (selective estrogen receptor degrader) |
|---|---|
| Mechanism | Pure ER antagonist — binds ER and induces its degradation, with no agonist activity. Standard of care second-line endocrine therapy for HR+/HER2- metastatic, especially after AI failure. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Workhorse 2L endocrine therapy. Combined with palbociclib (PALOMA-3), ribociclib (MONALEESA-3), abemaciclib (MONARCH-2) for CDK4/6i-naive disease, or after CDK4/6i progression as monotherapy or with alpelisib (PIK3CA-mutant).
Used By
Regimens
REG-ALPELISIB-FULVESTRANT-BREAST- Alpelisib + fulvestrant (HR+/HER2- PIK3CA-mutant metastatic post-AI/CDK4/6i)REG-CAPIVASERTIB-FULVESTRANT-BREAST- Capivasertib + fulvestrant (HR+/HER2- PIK3CA/AKT1/PTEN-altered metastatic post-AI/CDK4/6i)REG-FULVESTRANT-ABEMACICLIB- Fulvestrant + abemaciclib (HR+/HER2- metastatic 2L post-AI)REG-FULVESTRANT-EVEROLIMUS-BREAST- Fulvestrant + everolimus (HR+/HER2- metastatic post-AI/CDK4/6i, no targetable mutation)REG-INAVOLISIB-PALBO-FULV-BREAST- Inavolisib + palbociclib + fulvestrant (HR+/HER2- PIK3CA-mutant 1L metastatic post-adjuva...